Biotech Values

[DewDiligence]

Copaxone Continues to Clean Tysabri’s Clock in US Market

For MNTA investors, Copaxone’s US sales and market share are relevant as the economic underpinning for the generic-Copaxone program MNTA is undertaking with partner NVS.

Record 1Q09 sales of Copaxone (#msg-37542200) combined with the tepid 1Q09 sales of Tysabri (#msg-37091385) means that, in the US market, Copaxone is not only holding its ground against Tysabri, but also is gaining share at Tysabri’s expense while continuing to take share from the interferon drugs.

1Q09 US Sales of Copaxone and Tysabri

 
             1Q09 U.S.  Change 
             Sales($M)  vs 4Q08 
 Copaxone      430       +12% 
 Tysabri       116        +1% 

Source: Teva, Biogen Idec.